ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

HTR1A

5-hydroxytryptamine receptor 1A · also 5-HT1A, ADRB2RL1, ADRBRL1 · 5-hydroxytryptamine receptors, G protein-coupled

5 programs in company-led studies act on HTR1A, from 3 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
AripiprazoleruleOtsuka–phase 41312 runningDRD2, HTR2AChEMBL
VortioxetineruleH. Lundbeck–phase 4621 runningHTR3A, SLC6A4, SMSChEMBL
brexpiprazoleruleOtsuka–phase 4700 runningDRD2, HTR2AChEMBL
ulotarontruleOtsukaagonistphase 3305 runningTAAR1ChEMBL
ABBV-932AbbVieagonistphase 2103 runningDRD2, DRD3the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.